Bacterial or viral infection, that is the question. Haifa-Israel based MeMed Diagnostics is developing a point-of-care platform and immune-based test that will one day be able to provide answers.

Patients living with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), or multiple sclerosis must see their health practitioners frequently to check the progression of their conditions and their responses to therapies.

BGI has analyzed the world’s largest set of genome data from pregnant women, a total of 141,431 expectant mothers from across China.

After setting its sights on a $100 million IPO, CAR-T player Allogene Therapeutics has nearly tripled that, pricing the deal at the high end of the range and raising $288 million.

It's hard to believe it's been a full year since Abbott closed its acquisition of Alere, considering what a contentious deal it was and how hard Abbott fought last year to get out of it.

Thermo Fisher Scientific said recently that its third quarter revenues grew 16 percent, driven by growth across its four business segments.

Recently, CEC and WuXi AppTec announced the establishment of a joint venture company, Zhongdian Yaoming, to jointly cultivate the health care big data industry.

Illumina reported recently that its revenues for the third quarter grew 20 percent year over year, driven by growth across its sequencing and microarray products.

NeoGenomics recently announced a definitive agreement to acquire clinical oncology laboratory Genoptix for $125 million in cash and 1 million shares of NeoGenomics' stock.

GeneWiz, Nashville Biosciences Collaborate to Combine NGS Services, Biobank DNA Samples

Roche said recently that its diagnostics division revenues grew 6 percent in the first nine months of 2018, driven mainly by growing demand for its immunodiagnostics solutions.

Thermo Fisher Scientific announced recently that it has received CE-IVD marking for its Oncomine Dx Target Test.

Abbott recently said that its Diagnostics business grew sales 43 percent year over year.

The global Point of Care (POC) hematology diagnostics market is expected to grow at a CAGR of close to 9% over the forecast period 2018-2022 to reach a value of USD 2.7 billion by 2022

The global hemostasis/coagulation analyzers market was valued at USD 3.65 billion in 2017 and is expected to grow at a CAGR of 9.9% over the period 2018 to 2026 to reach USD 9.55 billion by 2026, driven mainly by the growing incidence of blood disorders.